Use of anti-diabetic drugs and glycaemic control in type 2 diabetes-The Hong Kong Diabetes Registry

被引:49
作者
Tong, Peter C. Y. [1 ,2 ]
Ko, Gary T. C. [2 ]
So, Wing-Yee [1 ]
Chiang, Sau-Chu [3 ]
Yang, Xilin [1 ]
Kong, Alice P. S. [1 ,4 ]
Ozaki, Risa [1 ]
Ma, Ronald C. W. [1 ]
Cockram, Clive S. [1 ]
Chow, Chun-Chung [1 ]
Chan, Juliana C. N. [1 ,2 ]
机构
[1] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Hong Kong Inst Diabet & Obes, Hong Kong, Hong Kong, Peoples R China
[3] Hosp Author, Chief Pharm Off, Hong Kong, Hong Kong, Peoples R China
[4] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China
关键词
Type; 2; diabetes; Drug treatment; Chinese; Glycaemic control;
D O I
10.1016/j.diabres.2008.09.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this report, we examined the usage of anti-diabetic treatments including oral antidiabetic drug (OAD) and/or insulin and their combination from baseline data of a consecutive cohort of 7549 Chinese type 2 diabetic subjects in the Hong Kong Diabetes Registry. Pattern of usage of anti-diabetic treatment and corresponding glycemic control was analyzed. OAD failure was defined as the need to add insulin to maintain glycemic target (glycated hemoglobin, HbA(1c) level < 7%) with or without continuation of OAD. There were 4109 [54.4%] women and 3440 [45.6%] men (age: median 57.0 years; range 13-92 years). The mean HbA(1c) level was 7.7 +/- 1.8% with 39.7% attaining glycemic target. Long disease duration was associated with more complex regimens and the respective rates of OAD failure requiring insulin use were 23.7%, 39.3%, 57.1% and 75.9% in those with disease duration < 5 years, 5-9.9 years, 10-19.9 years and >= 20 years (p < 0.001). In conclusion, in a clinic-based type 2 diabetic population, 39.7% attained glycemic target with HbA(1c) < 7%. Long disease duration and complexity of treatment regimens were associated with suboptimal glycemic control. Early intensification of therapy and system improvement are needed to enhance the effectiveness of these drugs in clinical practice. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:346 / 352
页数:7
相关论文
共 36 条
[1]  
[Anonymous], 2007, DIABETES CARE, DOI DOI 10.2337/DC07-S004
[2]   Glycaemic control in type 2 diabetes:: the impact of body weight,: β-cell function and patient education [J].
Chan, WB ;
Chan, JCN ;
Chow, CC ;
Yeung, VTF ;
So, WY ;
Li, JKY ;
Ko, GTC ;
Ma, RCW ;
Cockram, CS .
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 2000, 93 (03) :183-190
[3]   Oral combination therapy for type 2 diabetes [J].
Charpentier, G .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2002, 18 :S70-S76
[4]   Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (04) :486-494
[5]   The status of diabetes control in Asia - a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998 [J].
Chuang, LM ;
Tsai, ST ;
Huang, BY ;
Tai, TY .
DIABETIC MEDICINE, 2002, 19 (12) :978-985
[6]   Diabetes in urban African-Americans. XVI. Overcoming clinical inertia improves glycemic control in patients with type 2 diabetes [J].
Cook, CB ;
Ziemer, DC ;
El-Kebbi, IM ;
Gallina, DL ;
Dunbar, VG ;
Ernst, KL ;
Phillips, LS .
DIABETES CARE, 1999, 22 (09) :1494-1500
[7]   Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].
Dormandy, JA ;
Charbonnel, B ;
Eckland, DJA ;
Erdmann, E ;
Massi-Benedetti, M ;
Kmoules, IK ;
Skene, AM ;
Tan, MH ;
Lefébvre, PJ ;
Murray, GD ;
Standl, E ;
Wilcox, RG ;
Wlhelmsen, L ;
Betteridge, J ;
Birkeland, K ;
Golay, A ;
Heine, RJ ;
Korányi, L ;
Laakso, M ;
Mokán, M ;
Norkus, A ;
Pirags, V ;
Podar, T ;
Scheen, A ;
Scherbaum, W ;
Schernthaner, G ;
Schmitz, O ;
Skrha, J ;
Smith, U ;
Taton, J .
LANCET, 2005, 366 (9493) :1279-1289
[8]   Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus [J].
Evans, A ;
Krentz, AJ .
DRUG SAFETY, 1999, 21 (01) :7-22
[9]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[10]   Changing office practice and health care systems to facilitate diabetes self-management [J].
Martha M. Funnell ;
Robert M. Anderson .
Current Diabetes Reports, 2003, 3 (2) :127-133